Neupro rotigotine: Phase III data

A double-blind, Chinese Phase III trial in 247 adults with early stage idiopathic PD showed that once-daily 2-8 mg transdermal Neupro met the primary endpoint of reducing the sum of the total score of the UPDRS activities of daily living and motor examination subscales from baseline to week 24 vs. placebo (4.9 vs. 0.2 points, p<0.0001). Neupro also significantly reduced the individual subscores of the activities of daily living and motor examination subscales from baseline to week 24 vs. placebo (p<0.0001 and p=0.0004, respectively). Additionally, 42.3% of patients receiving Neupro were responders, defined as achieving a >=20% improvement in the UPDRS activities of daily living and motor examination subscales, vs. 22.3% of patients receiving placebo. Data were presented at the International Congress on Parkinson’s Disease and Movement Disorders in San Diego. ...